Entity

Time filter

Source Type

Irvine, CA, United States

Patent
Hitachi Chemical Research Center Inc. and Hitachi Ltd. | Date: 2012-12-10

Embodiments of the invention relate generally to methods of diagnosing diseases and measuring homeostatic states. In particular, the methods described here are used to characterize RNA from vesicles for expression of disease related markers. Embodiments of the invention also relate generally to the characterization of RNA by using sensitive techniques such as PCR to internally sample organ health using whole blood.


Patent
Hitachi Ltd., Cleveland Clinic and Hitachi Chemical Research Center Inc. | Date: 2011-05-03

Embodiments of the invention relate generally to ex vivo methods of quantifying expression of interferon responsive genes and characterizing an individuals potential responsiveness to interferon administration. Certain embodiments relate to methods to monitor the efficacy of ongoing interferon therapy by evaluating expression of interferon responsive genes before and after interferon administration.


Patent
Hitachi Ltd. and Hitachi Chemical Research Center Inc | Date: 2012-03-28

The present invention provides new materials that combine the advantages of well-defined polymeric starting materials and the convenience of surface modification by physical methods into one package and, thus, offers a general and powerful platform suitable for use in numerous applications.


Patent
Hitachi Chemical Research Center Inc. and Hitachi Ltd. | Date: 2011-10-31

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.


Patent
Hitachi Ltd., Shin Yokohama Kato Clinic and Hitachi Chemical Research Center Inc. | Date: 2012-07-18

Embodiments of the invention relate generally to ex vivo methods of quantifying expression of leukocyte-function associated mRNAs and using the quantification to characterize an individuals potential responsiveness to cancer immunotherapy. Certain embodiments relate to methods to monitor the efficacy of ongoing cancer immunotherapy by evaluating expression of leukocyte-function associated mRNAs genes before and administration of an anti-cancer immunotherapy regimen.

Discover hidden collaborations